Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $5.1807 (-0.78%) ($5.0400 - $5.6000) on Fri. Jun. 12, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.58% (three month average) | RSI | 48 | Latest Price | $5.1807(-0.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -3.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -9.2% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(29%) XBI(29%) ARKK(28%) IBUY(26%) ACES(25%) | Factors Impacting HTBX price | HTBX will decline at least -3.79% in a week (0% probabilities). VXX(-17%) VIXM(-13%) UUP(-11%) UNG(-8%) XLP(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.79% (StdDev 7.58%) | Hourly BBV | 0 () | Intraday Trend | -7.5% | | | |
|
Resistance Level | $5.85 | 5 Day Moving Average | $5.65(-8.31%) | 10 Day Moving Average | $5.82(-10.98%) | 20 Day Moving Average | $5.85(-11.44%) | To recent high | -33.3% | To recent low | 0% | Market Cap | $570m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |